RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

Key Takeaways Roche will move prasinezumab into phase III for early-stage Parkinson's disease based on phase II data. Prasinezumab showed clinical trends and biomarker effects despite missing its phase II primary endpoint. RHHBY holds exclusive rights and will pay royalties to Prothena under a 2013 licensing agreement. Roche (RHHBY) announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease.Roche has a licensing agreement with Prothena (PR ...